Trump’s Psychedelic Executive Order Is the Beginning of the End of Prohibition

My full analysis in written form adapted from my podcast with Dr. Matt Johnson.

On April 18th, President Trump signed one of the most consequential federal actions on psychedelics in modern American history: an executive order to accelerate research, regulatory review, and access to psychedelic therapies for serious mental illness.

The order does not legalize psychedelics. It does not end prohibition. And it does not mean psilocybin, MDMA, ibogaine, or any other psychedelic therapy is suddenly available at your local clinic.

But it does something culturally and politically enormous: it signals that the federal government is no longer treating psychedelic medicine as a fringe curiosity or countercultural taboo. It is treating it as a legitimate frontier in mental health care.

The White House order directs the FDA to provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designation; instructs the FDA and DEA to establish a Right to Try pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds; allocates at least $50 million through ARPA-H to support state-level psychedelic research programs; and directs federal agencies to prepare for faster rescheduling review once relevant products complete Phase 3 trials.

In plain English: the Trump administration is trying to speed up the pipeline, remove unnecessary bureaucratic drag, and prepare the federal government for the possibility that psychedelic therapies may soon receive FDA approval.

That is a massive shift.